LAUSR

It aimed to explore the adoption value of cuprous oxide nanoparticles (Cu2O NPs) in the clinical treatment of cervical cancer under the evaluation of real-time ultrasound elastography. In this experiment, the solution of Cu2O NPs was synthesized and used in 90 selected mouse models of cervical cancer. It was found that Cu2O NPs can significantly control the reproduction of various types of cervical cancer cells, effectively stopping the cycle of cervical cancer cell lines in the G1/G0 phase. In addition, the tumor weight of 0.25g in the Cu2O NPs group was notably lighter than that of 1.1g in the control group. The weight change of the mouse was 21g compared with 15g of the cis-dichlorodiamine platinum (CDDP) group, and it was proved that Cu2O NPs were less cytotoxic to the body and have few side effects. Moreover, real-time ultrasound elastography showed that there were 26 cases with a tumor elasticity score no less than 2 in the Cu2O NPs group, accounting for 87%, which was better than that of the CDDP group (17 cases, 57%), and the difference was substantial (P<0.05). The shear wave velocity of Cu2O NPs (1.46±0.48 m/s) was also lower than that (1.73±0.62 m/s) of the CDDP group, which suggested that the tumor body hardness of mice in the Cu2O NPs group was lower, and the difference was considerable (P<0.05). In short, Cu2O NPs had good functions such as inhibiting the proliferation and spread of tumor cells and blocking the cell cycle. Moreover, the toxic and side effects of the drug were slight, and it was an ideal new type of treatment for cervical cancer.